Picture of Cocrystal Pharma logo

COCP Cocrystal Pharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m-1.77%
3m-23.73%
6m-33.27%
1yr-36.92%
Volume Change (%)
10d/3m-25.71%
Price vs... (%)
52w High-53.42%
50d MA-0.09%
200d MA-23.84%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-59.94%
Return on Equity-48.31%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Cocrystal Pharma EPS forecast chart

Profile Summary

Cocrystal Pharma, Inc. is a biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. It is developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It also uses advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. The Company’s pipeline CC-42344 is an oral PB2 inhibitor discovered using Cocrystals proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus replication machinery is targeted.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
November 21st, 2014
Public Since
March 12th, 2018
No. of Shareholders
434
No. of Employees
12
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
10,173,790

COCP Share Price Performance

Upcoming Events for COCP

Q4 2023 Cocrystal Pharma Inc Earnings Release

Q1 2024 Cocrystal Pharma Inc Earnings Release

Cocrystal Pharma Inc Annual Shareholders Meeting

Q2 2024 Cocrystal Pharma Inc Earnings Release

Similar to COCP

Picture of 60 Degrees Pharmaceuticals logo

60 Degrees Pharmaceuticals

us flag iconNASDAQ Capital Market

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Acasti Pharma logo

Acasti Pharma

us flag iconNASDAQ Capital Market

Picture of Agriforce Growing Systems logo

Agriforce Growing Systems

us flag iconNASDAQ Capital Market

Picture of Akanda logo

Akanda

us flag iconNASDAQ Capital Market

FAQ